Background: Suicide helplines increasingly employ chat services to aid those in urgent need, but the wording and structure of text-driven exchanges may affect their effectiveness. Objective: Given the association of cognitive distortions with depression and anxiety, this study investigated their prevalence in the language of individuals seeking help from the Dutch 113 suicide helpline. Methods: We observed the prevalence of cognitive distortions for both help seekers and counselors in a large volume of chat sessions (N=71,148) of the Dutch 113 suicide chat helpline using natural language processing. The results were compared to 2 large collections of online text data from Dutch social media and web content. Results: We found that nearly all types of cognitive distortions are more prevalent in the language of help seekers compared to the control group of helpline counselors. Distortions of the personalizing, emotional reasoning, and mental filtering types were, respectively, 20.22, 7.87, and 4.53 times more prevalent among help seekers, revealing a distinct pattern of thought and language among individuals affected by suicidality. Conclusions: Our results raise the prospect of improving the effectiveness of online therapeutic interventions that target cognitive distortions through lexical analysis that detects the cognitive and lexical markers of suicidality.
<img src="https://jmir-production.s3.us-east-2.amazonaws.com/thumbs/00f57a522b7e20d230db8854f4090023" />
STAT+: AIDS group sues Trump administration over undisclosed agreement with Gilead
An AIDS activist group filed a lawsuit against the Trump administration for failing to disclose a research and development agreement that was at the heart of a settlement between the U.S. government and Gilead Sciences over patents for HIV prevention.
The settlement resolved a contentious lawsuit that was filed six years ago by the previous Trump administration after the Centers for Disease Control and Prevention maintained that Gilead infringed its patent rights. The agency had helped fund academic research that later formed the basis for two Gilead HIV pills, Truvada and Descovy.
The administration had alleged that Gilead ignored the contributions by CDC scientists, exaggerated its own role in developing HIV prevention drugs, and refused to sign a licensing agreement despite “multiple attempts” at reaching a deal after unfairly reaping hundreds of millions of dollars from research funded by taxpayers.
STAT+: FDA launches effort to speed up clinical trials, using AI
WASHINGTON — The Food and Drug Administration on Tuesday announced efforts to make clinical trials more efficient, starting by reviewing data in real time from trials conducted by AstraZeneca and Amgen.
The agency also asked the public to weigh in on a potential pilot program to work with companies that use AI to enhance safety monitoring and medication dose selections, identify safety signals, and improve patient recruitment in clinical trials.
AstraZeneca is conducting a Phase 2 trial of its combination therapy for patients with an aggressive form of lymphoma. The trial will take place at the University of Texas MD Anderson Cancer Center and the University of Pennsylvania. Amgen is conducting a Phase 1b trial of its treatment for small cell lung carcinoma. The trials will rely on a real-time data platform built by Paradigm Health.
Opinion: Healthcare or health care? Help STAT decide
The Associated Press Stylebook, the foundational journalism guide for how newsrooms report and write their stories, made waves last week when it decreed that “health care” should now be written as one word, not two. The change, announced at the annual ACES: The Society for Editing’s conference, was prompted by shifting usage and years of appeals to make the switch.
STAT closely follows AP style and has used “health care” since its founding in 2015. Now, we have to decide whether to adopt this new guidance, but our newsroom is divided.
Opinion: FDA commissioner: ‘Smarter,’ real-time clinical trials could transform drug development
Why does it take a new drug 10 years, on average, to come to market? Part of the reason lies in the dead time in the process.
Historically, trials have required tedious tabulations and repeated application submissions between phases, which is why 45% of the time from a Phase 1 trial until final submission is spent without any ongoing clinical trial in progress — idle time in the system.
<![CDATA[Study links schizophrenia’s earlier onset to higher genomic deletion CNV burden, showing future potential for personalized care.]]>
The Download: Musk and Altman’s legal showdown, and AI’s profit problem
This is today’s edition of The Download, our weekday newsletter that provides a daily dose of what’s going on in the world of technology.
Elon Musk and Sam Altman are going to court over OpenAI’s future
Elon Musk and OpenAI CEO Sam Altman head to trial this week in a case with sweeping consequences. Ahead of OpenAI’s IPO, the court could rule on whether the company can exist as a for-profit enterprise. It could even oust its leadership.
Musk, an OpenAI co-founder, claims he was deceived into bankrolling the firm under false pretenses. He’s seeking $134 billion in damages, the removal of Altman and president Greg Brockman, and the company’s restoration to a non-profit.
Find out how the trial could upend the global AI race.
—Michelle Kim
The missing step between hype and profit
In a celebrated South Park episode, a community of gnomes sneak out at night to steal underpants. Why? The gnomes present their pitch deck. “Phase 1: Collect underpants. Phase 2: ? Phase 3: Profit.” It’s a business plan that captures the current state of AI.
Companies have built the tech (Step 1) and promised transformation (Step 3). But how they get there is still a big question mark. Read about the potential paths forward.
—Will Douglas Heaven
This story originally appeared in The Algorithm, our weekly newsletter giving you the inside track on all things AI. Sign up to receive it in your inbox every Monday.
Welcome to the era of weaponized deepfakes
For years, experts have warned that deepfakes could be deployed in malicious ways. These dangers are now here.
Cheap, accessible models now produce weaponized deepfakes—from sexually explicit images to political propaganda—that look startlingly real. They’re already inciting violence, changing minds, and sowing mistrust, with women and marginalized groups disproportionately affected.
Experts fear that they’re cratering trust and critical thinking. Here’s why they’re alarmed.
—Eileen Guo
Weaponized deepfakes are on our list of the 10 Things That Matter in AI Right Now, MIT Technology Review’s guide to what’s really worth your attention in the busy, buzzy world of AI.
The must-reads
I’ve combed the internet to find you today’s most fun/important/scary/fascinating stories about technology.
1 OpenAI has ended its exclusive partnership with Microsoft
The new deal allows OpenAI to court rivals such as Amazon. (Reuters $)
+ Microsoft will still license OpenAI’s tech, but no longer exclusively. (NYT $)
+ OpenAI is missing key growth targets ahead of its IPO. (WSJ $)
2 Google has signed a classified AI deal with the Pentagon
It permits AI use for “any lawful government purpose.” (The Information $)
+ Over 600 Google workers had called for a block on the deal. (QZ)
+ AI firms are set to train military versions of their models on classified data. (MIT Technology Review)
3 The EU has told Google to open Android to AI rivals
It wants to end Gemini’s built-in advantage. (Ars Technica)
+ Google calls the move an “unwarranted intervention.” (WSJ $)
+ A final decision is expected by the end of July. (Reuters $)
4 OpenAI is reportedly developing an AI-first smartphone
It would replace apps with agents. (TechCrunch)
+ Qualcomm and MediaTek may be developing its processors. (Gizmodo)
5 A brain implant for depression is moving into human testing
The FDA has approved a human study of the device. (Wired $)
+ BCIs have thus far struggled to reach the market. (MIT Technology Review)
6 A populist backlash against AI is gaining momentum in rural America
From Indiana to Idaho, voters are pushing back against the technology. (NYT $)
+ Anti-AI protests are expanding worldwide. (MIT Technology Review)
7 DeepSeek has priced its new model 97% below OpenAI’s GPT-5.5
It aims to attract more enterprises, developers, and agent-based users. (SCMP)
+ Here are three reasons why DeepSeek V4 matters. (MIT Technology Review)
8 AI now generates a third of new websites
A study found it’s making the web more cheery and less verbose. (404 Media)
9 Top talent is leaving Big Tech to launch their own AI startups
Meta, Google, and OpenAI are facing a brain drain. (CNBC)
10 Taylor Swift is trademarking her voice and image
The Grammy winner has been the target of numerous deepfakes. (NBC News)
+ A growing number of celebrities are fighting AI with trademarks. (BBC)
Quote of the day
“The reality is people don’t like him.”
—Judge Yvonne Gonzalez Rogers reacts to prospective jurors confessing their negative views of Elon Musk ahead of his legal battle with Sam Altman, The Verge reports.
One More Thing
How covid conspiracy theories led to an alarming resurgence in AIDS denialism
When Joe Rogan falsely declared that “party drugs” were an “important factor in AIDS,” several million people were listening. He also asserted that AZT, the earliest drug used to treat AIDS, killed people “quicker” than the disease itself—another claim that has been disproven.
Such comments illustrate an unmistakable resurgence in AIDS denialism: a false collection of theories arguing either that HIV does not cause AIDS or that there is no such thing as HIV at all. By the dawn of the millennium, these claims had largely fallen out of favour. That changed when the coronavirus arrived.
Follow the digital path from Covid skepticism to the return of a deadly conspiracy theory.
—Anna Merlan
We can still have nice things
A place for comfort, fun and distraction to brighten up your day. (Got any ideas? Drop me a line.)
+ Explore the planets from your laptop with this live sky map.
+ This marathon DJ set from Daphni is an incredible journey through electronic music.
+ NASA’s stunning Artemis II wallpapers bring a high-res piece of deep space to your phone.
+ This fascinating GPS explainer breaks down how your phone figures out exactly where you are.
A structured narrative review on VNS-treated drug-resistant epilepsy: EEG markers, neurochemical mechanisms, and future biomarker-driven computational directions
Vagus nerve stimulation (VNS) is an established adjunctive therapy for drug-resistant epilepsy. Experimental and clinical evidence indicates that its therapeutic effects involve distributed brain networks and multiple neurochemical pathways. Electroencephalography (EEG) has been widely used to characterize VNS-related neurophysiological changes, including alterations in conventional oscillatory activity, functional connectivity, and, more recently, aperiodic spectral components such as the spectral exponent and spectral offset. However, these EEG findings are often interpreted without sufficient consideration of the neurochemical intermediates that may contribute to the observed electrophysiological changes. In this structured narrative review, primarily focused on epilepsy, we examine how VNS-related EEG findings can be interpreted in light of noradrenergic, serotonergic, cholinergic, GABAergic, and neurotrophic mechanisms. We also discuss methodological challenges in the analysis of periodic and aperiodic EEG components and outline how machine learning approaches and adaptive closed-loop neuromodulation strategies may support the development of clinically useful VNS biomarkers.
Functional connectivity changes in the thalamocortical network due to neck pain and the multiscale regulatory effects of acupuncture: a cross-scale multi-omics neuroimaging study
BackgroundNeck pain correlates with multiscale brain abnormalities, but cross-scale mechanisms of acupuncture analgesia are unclear. This study aimed to: (1) Explore differential modulation of thalamic functional networks by verum vs. sham acupuncture; (2) Examine associations between functional connectivity changes and micro gene expression to unravel its multiscale mechanisms.MethodsA total of 130 participants were initially enrolled, and 100 eligible neck pain patients were randomized 1:1 to the verum (n = 50) or sham (n = 50) acupuncture groups. Finally, 49 patients in each group were included for the final analysis due to one case of exclusion in each group, with treatment administered twice a week for 2 weeks. Visual Analog Scale (VAS), resting-state functional magnetic resonance imaging (fMRI), and Allen Human Brain Atlas (AHBA) transcriptome data were analyzed via Partial Least Squares (PLS) regression.ResultsBoth groups showed reduced post-treatment VAS (p < 0.001), with the verum group exhibiting a superior effect (Z = −6.877, p < 0.001). Neuroimaging revealed that verum acupuncture (VA) specifically induced significant decreases in functional connectivity (FC) between the right thalamus and left anterior cingulate cortex (T = −4.498) as well as between the right thalamus and right Rolandic operculum (T = −4.532, voxel-level p < 0.01, cluster-level p < 0.05), an effect absent in the sham acupuncture group (SA). Gene- FC association analysis indicated that PLS2 component explained 39.83% of FC variance (Pspin: permutation test p < 0.05), with weight genes showing significant spatial correlation to connectivity changes (r = 0.445, Pspin = 0.0011). A total of 809 genes were enriched in the innate immune response and phosphorylation regulation pathways, whereas 1,222 genes were enriched in the GABA-ergic synapse and synaptic membrane-related pathways.ConclusionVA relieves pain via modulating thalamus-anterior cingulate cortex networks, involving immune-inflammation and neural inhibition, providing first multi-scale validation integrating neuroimaging and transcriptomics.Clinical trial registrationThis trial was registered with the International Traditional Medicine Clinical Trial Registry (registration number: ITMCTR2023000001) prior to participant enrollment.